论文部分内容阅读
我市从1988年开始按W??O的MDT(1981)方案,分别采用国产B663(南京江浦制药厂批号为870011)与国外B663进行疗效对比观察.现将初步疗效报告如下: 一、病例情况及疗法病例情况:120例中有新发现病例、复发病例、曾用单-DDS和DDS+RFP但治疗不规则、而未达福州会议临床治疗标准的病例. 疗法:对120例多菌型病例随机分为国外组101例和国内组19例(因国产药品有限).统一实施三联化疗24个月,B663 300mg/月、RFP(D)600mg/月(送药看服),
The city from 1988 to start MDO (1981) program, respectively, using domestic B663 (Nanjing Jiangpu Pharmaceutical Factory lot number 870011) and foreign B663 for the comparison of the efficacy of the current report is as follows: First, the case And treatment cases: 120 cases of newly discovered cases, recurrent cases, once treated with single-DDS and DDS RFP but irregular, but not up to the clinical treatment of Fuzhou meeting the standard case.Methods: 120 cases of multi-bacteria cases Randomly divided into foreign group of 101 cases and domestic group of 19 cases (due to limited domestic drugs.) Uniform implementation of triple chemotherapy 24 months, B663 300mg / month, RFP (D) 600mg / month